Using HLA reactivity levels, this laboratory estimate shows how broadly your immune system reacts to antigens that could appear on a donated kidney. A higher score can reflect more antibodies or stronger antibody binding, which may complicate donor matching. Your transplant team uses it to estimate sensitization, but it does not determine eligibility by itself.
This guide explains Panel Reactive Antibody scores for people awaiting a kidney transplant, covering immune sensitization, result ranges, related antibody tests, and how transplant teams interpret PRA during donor matching.
Kidney Matching Begins With Immune Sensitization
Finding an immune-compatible exchange is only one part of matching a kidney transplant candidate with a suitable donor. Pregnancy, blood transfusions, and previous transplants can expose your immune system to HLA markers, teaching it to recognize those markers as foreign.
Anti-HLA antibodies drive part of that response. A broad panel reactive antibody screen detects this activity against many targets and gives your team a snapshot of your sensitization level. Greater sensitization can make a compatible kidney harder to find.
Your history gives the percentage useful context. Your transplant center may combine it with your current antibodies, crossmatch result, medical record, and other clinical findings. Treat your score as one component of matching, not a standalone verdict.
- HLA markers: These molecules help immune cells identify cells, tissues, and foreign material.
- Antibody breadth: This describes how many different HLA targets react with your blood sample.
- Antibody strength: This reflects the strength of detected antibody binding in some assay formats.
- Sensitization level: This describes your immune system’s tendency to react against foreign HLA markers.
- Donor matching: Your antibody patterns help your team identify which donor offers warrant closer review.
What the Panel Reactive Antibody Test Measures
By screening your blood, this test identifies antibodies that react with a broad collection of HLA targets. It estimates the percentage reacting, the strength of the signal, or both, depending on the laboratory method.
Laboratories may report class I, class II, or combined results because HLA antibodies belong to different classes. PRAB is another abbreviation sometimes used for the broad antibody screen, rather than a separate biological test.
Don’t confuse human kidney matching with Progressive Retinal Atrophy, or PRA, in dogs. Veterinary PRA is retinal degeneration assessed through a different testing framework involving DNA testing, genetic inheritance, and autosomal recessive inheritance. A human PRA percentage has no meaning for a Yorkshire Terrier’s affected status or carrier status.
| Reported measure | What it represents | Why it matters to you |
|---|---|---|
| Percent reactivity | The percentage of panel targets that react with your sample. | It provides a broad view of your antibody breadth. |
| Class I PRA | Reactivity involving HLA class I targets. | It helps your team evaluate possible incompatibilities. |
| Class II PRA | Reactivity involving HLA class II targets. | It adds information to your sensitization review. |
| Mean fluorescence intensity | The brightness of bead signals in some bead-based assays. | It may help describe antibody-binding strength. |
How the Score Is Calculated
Calculation methods vary by laboratory. A classic percentage may count reactive panel members, while a calculated score may use a percentile based on reaction breadth and strength. Luminex bead-based assays can report mean fluorescence intensity and separate class I from class II results.
Two reports can therefore look different even when they describe similar antibody activity. The panel, assay, positivity threshold, and calculation method all affect interpretation. Compare those methods before comparing two percentages directly.
Your result is a calculated screening estimate, not a direct measurement of kidney survival or rejection risk. A donor-specific antibody screen and crossmatch provide more focused information about a particular donor.
PRA Score Interpretation Across Result Ranges
A high percentage generally indicates broader or stronger HLA antibody reactivity. An 80% result creates different matching considerations from a 5% result, but neither number reveals every relevant antibody. Your team must review the pattern, strength, and specificity.
A high PRA can limit the number of donor kidneys whose HLA markers avoid your antibodies. Your transplant center may need more extensive matching, and donor offers may require closer review. A high result does not automatically make a transplant impossible.
| Result pattern | Plain-language meaning | Matching implication for you |
|---|---|---|
| Low PRA | Your sample showed little or limited reactivity against the panel targets. | Your donor options may be broader, although uncommon antibodies can still matter. |
| Moderate PRA | Your sample reacted with some panel targets. | Your team may need a more detailed antibody and donor review. |
| High PRA | Your sample reacted with many targets, produced stronger signals, or showed both. | Your center may have more difficulty locating compatible donor options. |
A low panel reactive antibody level does not exclude antibodies against rare HLA antigens missing from the panel. It also cannot predict rejection with certainty. Current donor-specific findings carry more direct weight when your team reviews an offer.
A 0% PRA percentage means your sample showed no meaningful reactivity against the targets included in that panel. It does not prove that antibodies exist against no possible HLA antigen, and it does not guarantee compatibility with every donor.
Ask your transplant team which panel and assay produced the result, whether it reports percent reactivity, fluorescence intensity, or a calculated score, and which threshold the laboratory used.
PRA, PRAB, and Donor-Specific Antibody Screening
On laboratory reports, PRAB and PRA may describe the same broad screening approach for immune antibodies. A donor-specific antibody screen answers a narrower question by testing HLA targets associated with a particular donor.
| Feature | PRA or PRAB | Donor-specific antibody screen |
|---|---|---|
| Scope | A broad panel of HLA targets | HLA targets associated with one donor |
| Main role | Shows your sensitization and general matching difficulty | Evaluates a specific donor offer |
| Timing | May be repeated as your immune profile changes | Usually reviewed during donor evaluation |
| Limitation | May miss uncommon targets | Cannot show your full broad antibody pattern |
Your broad screen might show reactivity across many class I targets. A donor-specific screen may then reveal whether that donor’s HLA markers fall within the reactive group. The second result does not replace your PRA history because it answers a different matching question.
A crossmatch may bring your blood or antibodies into contact with donor cells. That result adds information about immune compatibility, but your team still considers the clinical context and test method. No single laboratory result overrides the full evaluation.
Using PRA in Transplant Evaluation
PRA helps your team estimate how sensitized your immune system is and how difficult donor matching may become. The result provides context for candidacy, but your center evaluates it alongside medical, immune, and kidney-function findings.
A high PRA alone does not disqualify you from transplantation. Eligibility depends on the full assessment, including your health, other medical conditions, adherence to care, and your transplant program’s requirements. A difficult matching path can still end in a transplant.
Your sensitization status may affect transplant waitlist priority, although the exact role depends on applicable policy. In the United States, the Organ Procurement and Transplantation Network oversees kidney allocation policies. UNOS operates the computer system used for organ matching and allocation.
Computed PRA, or cPRA, is related to PRA but serves a different function. A laboratory PRA reports measured or calculated antibody reactivity, while cPRA estimates matching difficulty under allocation rules. Your transplant center can clarify which measure your report uses.
Transplant Center Review Checklist
- Check the date: Confirm when the test was performed because your antibody profile can change.
- Confirm class results: Determine whether the report includes class I, class II, or combined results.
- Review the method: Identify the assay, panel, threshold, and calculation method behind the percentage.
- Compare the history: Look for changes following transfusions, pregnancy, transplantation, or other immune events.
- Review donor data: Examine donor-specific antibody findings after receiving an offer.
- Assess crossmatch data: Interpret the crossmatch with your transplant team rather than through PRA alone.
You don’t need to decode every laboratory term by yourself. Request the complete report, its date, the method used, and your transplant team’s explanation of how the result affects your evaluation.
Why One PRA Result Cannot Stand Alone
Your antibody profile may change after pregnancy, a blood transfusion, a transplant, or another immune event. An older result can reveal a pattern over time, but it cannot replace current screening during donor evaluation. Your result date therefore matters.
Assay differences create another limitation. One laboratory may use cell-based methods, while another uses fluorescent bead technology or reports a calculated percentile. Panel coverage can differ, so a low result from one panel may miss rare antibodies detectable elsewhere.
You should review every report with the specialist team responsible for your kidney transplant. That review is especially important when your center considers a donor offer, updates waitlist information, or reassesses your sensitization level.
Human PRA and veterinary PRA share an abbreviation but not a test. A Yorkshire Terrier’s canine PRA evaluation may use DNA testing to identify carrier status and affected status. Genetic counseling can explain autosomal recessive inheritance and the risk of retinal degeneration to responsible breeders or owners.
Key Takeaways for Your Kidney Evaluation
Your PRA score estimates the breadth or strength of anti-HLA antibody reactivity that may affect kidney matching. Your donor-specific antibody screen, crossmatch, history, and transplant-center assessment provide the broader context.
Your percentage should never serve as a decision on its own. Request the complete report, identify the assay and calculation method, and ask your transplant team how the findings apply to a current donor offer or your transplant waitlist priority.
Kidney Transplant Questions
What is a Panel Reactive Antibody PRA score?
Based on HLA reactivity levels, this estimate shows how broadly your immune system responds to targets on a possible donor kidney. A higher result can indicate broader or stronger antibody reactivity, which may complicate donor matching.
What does a PRA score measure?
A PRA score measures how your blood reacts to a broad panel of HLA targets. Your result estimates the breadth or strength of your anti-HLA antibody reactivity that may matter during kidney matching.
How is the PRA score calculated?
Laboratories calculate PRA results in different ways. Your report may use the percentage of reactive panel targets, mean fluorescence intensity, or a calculated percentile based on the breadth and strength of your antibody reactions.
What does a 0% PRA score mean?
Testing detected no meaningful reactivity against the targets included in your laboratory’s panel in this sample. Your score does not exclude antibodies against every possible HLA antigen or predict donor compatibility with certainty.
What does a high PRA score indicate?
Broader or stronger HLA antibody reactivity against a broad range of targets generally appears in a high PRA score. Your transplant team may have more difficulty finding compatible donor kidneys, but your score alone does not determine eligibility or guarantee an outcome.
Does a clear PRA DNA test result guarantee a dog will not develop PRA?
Even with a clear veterinary DNA result, a dog may still develop Progressive Retinal Atrophy later in life. It describes the test’s relevant genetic result, but an affected clinical status and the cause of retinal degeneration require veterinary evaluation.
What does a clear PRA result mean?
No meaningful reactivity was detected against the targets included in the laboratory panel in this human sample. It does not exclude antibodies against rare HLA antigens or guarantee compatibility with a particular donor.
What does it mean if a dog is a PRA carrier?
A dog identified as a PRA carrier has one altered copy of the relevant gene under autosomal recessive inheritance. A carrier generally is not genetically affected, but the altered allele can be passed to offspring and affects breeding decisions.
Can a PRA carrier develop progressive retinal atrophy?
Dogs carrying one recessive PRA allele without showing the condition generally do not develop canine Progressive Retinal Atrophy. Apparent vision loss still warrants an examination because eye disease can have other causes.
How is PRA inherited in dogs?
Canine Progressive Retinal Atrophy is commonly evaluated as an autosomal recessive condition. An affected dog inherits two disease-associated alleles, while a carrier generally has one and an unaffected, noncarrier dog has neither.
How should a PRA result affect breeding decisions?
Identifying carriers and affected dogs through PRA results can help guide responsible breeding decisions. DNA testing and genetic counseling help you interpret the autosomal recessive inheritance pattern, carrier status, and affected status before selecting a mating.
What should an owner do if a dog has a PRA-affected result?
When a dog receives an affected canine PRA result, arrange veterinary follow-up, document vision changes, and avoid transmitting the condition through breeding. Your veterinarian can assess retinal degeneration and discuss long-term care.
Is a PRA score the same as cPRA?
Your PRA and cPRA values are related but not identical. PRA generally describes your laboratory antibody-reactivity result, while cPRA estimates matching difficulty for kidney allocation under applicable rules.
How can PRA affect transplant waitlist priority?
Kidney allocation policies may consider PRA-related sensitization when determining transplant waitlist priority under applicable rules. OPTN and UNOS use specific rules, so your transplant center should explain how your result applies.
